Cure or cause: Opposing roles for zinc in age-related macular degeneration

Expert Review of Ophthalmology

Volumn 3, Issue 1, 2008, Pages 1-4

  Lengyel, Imre ^a   Peto, Tünde ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT FACTOR H; VITAMIN; ZINC; ZINC ACETATE; ZINC OXIDE;

AGE DISTRIBUTION; ALZHEIMER DISEASE; BRUCH MEMBRANE; CHOROID VASCULARIZATION; CLINICAL TRIAL; DIETARY INTAKE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; EDITORIAL; ENVIRONMENTAL FACTOR; ENZYME REGULATION; GENETIC ASSOCIATION; HUMAN; LONG TERM CARE; OLIGOMERIZATION; PATHOGENESIS; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL IMPAIRMENT; ZINC METABOLISM;

EID: 47249106092     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.1.1     Document Type: Editorial

References (38)

1. Bird AC. The Bowman lecture. Towards an understanding of age-related macular disease. Eye 17(4), 457-466 (2003).
2. Evans J. Causes of blindness and partial sight in England and Wales. In: Studies on Medical and Population Subjects. HMsS (Ed.). London, UK 1990-1991 (1995).
3. Leibowitz HM, Krueger DE, Maunder LR et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv. Ophthalmol. 24(Suppl.), 335-610 (1980).
4. Ross RJ, Verma V, Rosenberg KI, Chan CC, Tuo J. Genetic markers and biomarkers for age-related macular degeneration. Expert Rev. Ophthalmol. 2(3), 443-457 (2007).
5. Lengyel I, Tufail A, Hosaini HA, Luthert P, Bird AC, Jeffery G. Association of drusen deposition with choroidal intercapillary pillars in the aging human eye. Invest. Ophthalmol. Vis. Sci. 45 (9), 2886-2892 (2004).
6. Donati G. Emerging therapies for neovascular age-related macular degeneration: state of the art. Ophthalmologica 221(6), 366-377 (2007).
7. DiSilvestro RA. Zinc in relation to diabetes and oxidative disease. J. Nutr. 130(5S Suppl.), 1509S-1511S (2000).
8. Evans JR, Henshaw K. Antioxidant vitamin and mineral supplementation for preventing age-related macular degeneration. Cochrane Database Syst. Rev. 2, CD000253 (2000).
9. Chong EW, Wong TY, Kreis AJ, Simpson JA, Guymer RH. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 335(7623), 755 (2007).
10. Evans JR. Antioxidant vitamin and mineral supplements for age-related macular degeneration. Cochrane Database Syst. Rev. 2, CD000254 (2002).
11. van Leeuwen R, Boekhoorn S, Vingerling JR et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 294(24), 3101-3107 (2005).
12. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins c and e, β carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch. Ophthalmol. 119(10), 1417-1436 (2001).
13. Maret W, Sandstead HH. Zinc requirements and the risks and benefits of zinc supplementation. J. Trace Elem. Med. Biol. 20(1), 3-18 (2006).
14. Johnson AR, Munoz A, Gottlieb JL, Jarrard DF. High dose zinc increases hospital admissions due to genitourinary complications. J. Urol. 177(2), 639-643 (2007).
15. Hyun HJ, Sohn JH, Ha DW, Ahn YH, Koh JY, Ybon YH. Depletion of intracellular zinc and copper with TPEN results in apoptosis of cultured human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 42(2), 460-465 (2001).
16. 2+- induced cell death is mediated by the induction of intracellular ROS in ARPE-19 cells. Curr. Eye Res. 28(3), 195-201 (2004).
17. Newsome DA, Miceli MV, Tate DJ, Alcock NW, Oliver PD. Zinc content of human retinal pigment epithelium decreases with age and macular degeneration, but superoxide dismutase activity increases. The Journal of Trace Elements in Experimental Medicine, 8 (4), 193-199 (1996).
18. Miceli MV, Tate DJ Jr, Alcock NW, Newsome DA. Zinc deficiency and oxidative stress in the retina of pigmented rats. Invest. Ophthalmol. Vis. Sci. 40(6), 1238-1244 (1999).
19. Kennedy CJ, Rakoczy PE, Robertson TA, Papadimitriou JM, Constable IJ. Kinetic studies on phagocytosis and lysosomal digestion of rod outer segments by human retinal pigment epithelial cells in vitro. Exp. Cell Res. 210(2), 209-214 (1994).
20. Schraermeyer U, Peters S, Thumann G, Kociok N, Heimann K. Melanin granules of retinal pigment epithelium are connected with the lysosomal degradation pathway. Exp. Eye Res. 68(2), 237-245 (1999).
21. Ames BN. Micronutrient deficiencies. A major cause of DNA damage. Ann. NY Acad. Sci. 889, 87-106 (1999).
22. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20(6), 705-732 (2001).
23. Rink L, Gabriel P. Zinc and the immune system. Proc. Nutr. Soc. 59, 541-552 (2000).
24. Clemons TE, Kurinij N, Sperduto RD. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch. Ophthalmol. 122(5), 716-726 (2004).
25. Lengyel I, Flinn JM, Peto T et al. High concentration of zinc in sub-retinal pigment epithelial deposits. Exp. Eye Res. 84(4), 772-780 (2007).
26. Magnusson KP, Duan S, Sigurdsson H et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 3(1), e5 (2005).
27. Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. USA 102(20), 7227-7232 (2005).
28. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 308(5720), 385-389 (2005).
29. Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720), 419-421 (2005).
30. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 308(5720), 421-424 (2005).
31. Crossley LG, Porter RR. Purification of the human complement control protein C3b inactivator. Biochem. J. 191(1), 173-182 (1980).
32. Perkins SJ, Nealis AS, Sim RB. Oligomeric domain structure of human complement factor H by X-ray and neutron solution scattering. Biochemistry 30(11), 2847-2857 (1991).
33. Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum. Mutat. 27(1), 21-30 (2006).
34. Turnberg D, Botto M. The regulation of the complement system: insights from genetically-engineered mice. Mol. Immunol. 40(2-4), 145-153 (2003).
35. Frederickson CJ, Koh JY, Bush AI. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 6(6), 449-462 (2005).
36. Suh SW, Jensen KB, Jensen MS et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 852(2), 274-278 (2000).
37. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23(6), 1031-1038 (2002).
38. Ugarte M, Osborne NN. Zinc in the retina. Prog. Neurobiol. 64(3), 219-249 (2001).